Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Shivers; Nausea; This non-serious case was reported by a consumer via call center representative and described the occurrence of shivers in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included evolocumab (Repatha), glipizide and benazepril. On 28-FEB-2025, the patient received the 1st dose of Shingrix. On 05-MAR-2025, 5 days after receiving Shingrix, the patient experienced shivers (Verbatim: Shivers) and nausea (Verbatim: Nausea). The outcome of the shivers and nausea were unknown. It was unknown if the reporter considered the shivers and nausea to be related to Shingrix. It was unknown if the company considered the shivers and nausea to be related to Shingrix. Additional Information: GSK Receipt Date : 05-MAR-2025. The reporter is the patient. The patient received the first dose of SHINGRIX last Friday at a local pharmacy. About 2 hours ago 3pm ET , on the day of reporting , the patient was began experienced shivers and nausea.
REPATHA; GLIPIZIDE; BENAZEPRIL